Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05427084
PHASE2/PHASE3

Canagliflozin Targeting Vascular Inflammation

Sponsor: Ottawa Heart Institute Research Corporation

View on ClinicalTrials.gov

Summary

CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.

Official title: Canagliflozin Targeting Vascular Inflammation: an Ottawa Imaging Study - a Pilot Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2024-11-15

Completion Date

2026-12

Last Updated

2024-12-11

Healthy Volunteers

No

Interventions

DRUG

Canagliflozin

Canagliflozin tablet 300mg PO daily

DRUG

Placebo

Placebo tablet

Locations (1)

University of Ottawa Heart Institute

Ottawa, Ontario, Canada